Introduction
Chronic spontaneous urticaria (CSU) is a relatively frequent disease, affecting up to 1 % of the general population at some point in life. It is characterized by recurrent or persistent itch, wheals and in about one half of cases also by angioedema for more than 6 weeks. In severe cases, it may become a heavily disturbing problem that markedly worsens the quality of life of patients. The disease is caused by the release of histamine from mast cells and basophils with the contribution of other biologically active substances including platelet activating factor, neuropeptides, arachidonic acid metabolites such as PGD2, LTC4, LTD4, and LTE4, and serotonin. The anaphylatoxins C3a and C5a may also play a role in the pathogenesis. These substances contribute to the appearance of erythema, wheals, and itch by inducing vasodilation, increasing vascular permeability, and stimulating sensory nerve endings [1] . Autoimmune mechanisms, particularly IgG autoantibodies specific for the high affinity IgE receptor, FcεRI, or for IgE [2, 3] may also participate to the pathogenesis of the disease in a proportion of patients (about 40-50 %). In recent years, the coagulation cascade activation has added to this already complex pathogenic picture. The present review will examine the current knowledge on this topic and discuss possible alternative treatments for patients not responding to standard therapies Coagulation and Chronic Urticaria ( Fig. 1) In recent years, a relevant piece of evidence has appeared in the medical literature suggesting that the coagulation cascade might be involved in the pathophysiology of chronic spontaneous urticaria [4] [5] [6] [7] [8] . The first observations in this sense, published in 2006, noted that chronic urticaria is associated with elevated plasma levels of prothrombin fragment F1+2, a marker of thrombin generation, and that such levels parallel the disease severity [9] . Subsequent studies found that thrombin generation is associated with the activation of the extrinsic pathway of coagulation as shown by increased plasma levels of activated factor VII (FVIIa) [10] . In patients with severe urticaria, the activation of the coagulation cascade may be intense enough to lead to fibrinolysis, as shown by an increase in plasma levels of Ddimer paralleling disease severity [11] . In keeping with the findings by Moosbauer et al. [12] showing that eosinophils are a major intravascular source of tissue factor, Cugno et al. were able to demonstrate that eosinophils are the main cells expressing TF in chronic urticaria [13] . What initiates the activation of eosinophils is still unclear. One study was able to show the presence of circulating autoantibodies to FcεRII, the low affinity IgE receptor [14] , in about 70 % of CU patients. The major basic protein (MBP), released by the eosinophils activated by such autoantibodies, would cause mast cell degranulation [14] . Interestingly, eosinophils might be in turn activated and recruited by mediators, cytokines, chemokines, or other as yet unknown factors released by mast cells [15] [16] [17] [18] . The findings summarized above have been confirmed by several independent groups [19] [20] [21] [22] [23] [24] [25] [26] . Thus, it seems likely that coagulation may play a role in the pathogenesis of chronic urticaria. In animal models, thrombin induces MC degranulation with potency similar to that of FcεRI-mediated activation [27] . Mast cell activation by coagulation factors occurs via the so-called protease-activated receptors 1 and 2 (PAR-1 and PAR-2). Thrombin is able to activate the mast cell via PAR-1, while TF+factor VIIa (FVIIa) and factor Va (FVa)+factor Xa (FXa) complexes act via PAR-2 [28, 29] . The activation of PAR-1 and/or PAR-2 receptors leads to mast cell degranulation. In turn, tryptase released by mast cells is able to activate directly prothrombin, thus generating thrombin [30] , and giving rise to an amplification loop. Further, thrombin may increase vascular permeability by a direct effect on endothelial cells [29] [30] [31] [32] [33] and can activate C5 to C5a in the absence of C3, thus bypassing the first stage of the complement cascade [34] . The increased levels of activated complement component 5 (C5a) in patients with active CU support the possible involvement of complement system in the pathophysiology of the disease [24] . The activation of the coagulation cascade correlates with disease severity in all studies carried out so far, and plasma levels of commonly measurable factors drop during the remission phases.
Coagulation Cascade Activation and Inflammation
Active CU is characterized by a perivascular, nonnecrotizing infiltrate of Th1 and Th2 lymphocytes, monocytes, neutrophils, eosinophils, and basophils [35, 36] , and by a systemic inflammatory process, as shown by the frequent increase in circulating C reactive protein (CRP), interleukin-6 (IL-6), and matrix metalloprotease 9 (MMP-9) [37, 38] . Immune response, inflammation, and coagulation [39, 40] are closely linked to each other. The expression of tissue factor (TF), the main initiator of blood coagulation, is induced by pro-inflammatory cytokines such as IL-6 and tumor necrosis factor alpha (TNF-α) [40] . Proteases, such as several activated coagulation factors, are able to induce the expression of inflammatory cytokines by activating protease-activated receptors (PARs) present on effector cells [41] . Thus, coagulation and inflammation are able to activate each other increasing their respective effects.
D-Dimer as Predictor of Response to Treatment
Recent studies show that the elevated plasma levels of Ddimer, although not specific for chronic urticaria (as they can be observed in a number of other inflammatory processes) may be used as a biomarker of a severe disease that is often resistant to antihistamine treatment [11, 42•, 43] , and sometimes to ciclosporin as well [44•] .
Is There Thrombophilia in Chronic Spontaneous Urticaria? Although, theoretically, the hypercoagulation state that characterizes CSU might be associated with an increased risk of thrombosis, no increased incidence of thrombotic events has been reported so far. This might be due in part not only to the presence of an efficient thombolytic system but also to a predominant extravascular location of fibrin deposition, suggesting that the coagulation cascade observed in CSU occurs extravascularly [21] . It has been suggested that patients with long-term CSU, accompanied by systemic inflammation, particularly with raised blood levels of CRP, may have an increased risk of cardiovascular disorders [45] although other observations indicated that the hypercoagulation occurring in CSU and AE is unlikely to be associated with an increased risk of thrombosis, in contrast to patients with acute urticaria [8] or with other skin diseases such as bullous pemphigoid [46] .
Anticoagulants/Antifibrinolytics in Chronic Spontaneous Urticaria
Although the exact role of the activation of coagulation/ fibrinolysis in the pathogenesis of CSU has still to be defined, the fact that such an activation parallels the activity of the disease [11, 47] provides theoretically a rationale to test effects of anticoagulant and antifibrinolytic therapy in patients with severe forms. A small double-blind, placebo-controlled study carried out about 15 years ago first detected the effectiveness of oral anticoagulant therapy in some patients with refractory CSU [48] . After an attempt carried out more than 60 years ago [49] , in some more recent studies, heparin also has been effective in patients with severe disease [50, 51] and elevated D-dimer plasma levels [52] . In the first study [50] , a 43-year-old woman with antihistamine-resistant chronic urticaria responded well to heparin therapy. In the second one [51] , a 59-year-old woman who had been suffering from CSU for 7 years was successfully treated first with nadroparin and then with acenocoumarol which has been given due to an intercurrent deep vein thrombosis. Finally, in the latter study, nadroparin (11,400 IU per day) and tranexamic acid (given orally 1 g three times a day for 2 weeks), given as an add-on therapy in patients under H1-antihistamine treatment, induced a significant decrease in disease symptoms in five of eight patients [52] . In contrast, tranexamic acid given alone has produced less convincing results; in fact, a reduction in the frequency of CSU attacks was reported in two patients [53] , whereas no significant differences were found between tranexamic acid and placebo treatment in a double-blind study performed in 17 patients [54] . Two other serine protease inhibitors effective on coagulation and fibrinolysis, named nafamostat mesilate and camostat mesilate, were shown to improve symptoms in two patients with refractory CSU [55] . Interestingly, these drugs inhibit different proteases, including tryptase, kallikrein, complement, factor XII, and plasmin, and show an anticoagulant effect similar to that of heparin [56] .
Conclusions
There is increasing evidence that the coagulation cascade has the potential to play a role in the pathogenesis of chronic spontaneous urticaria, particularly in severe cases. Scattered reports of the efficacy of drugs interfering at different levels with the activation of this system indirectly support such concept. It is well known that about one fourth of patients with severe, antihistamine-resistant, chronic urticaria do not respond to second-level treatments such as omalizumab or ciclosporin. While data in patients not responding to omalizumab are missing, it is quite clear that in ciclosporin-resistant patients, the coagulation cascade is heavily activated [44•] . Interestingly, effective omalizumab treatment is associated with a decrease in D-dimer levels in patients with chronic urticaria [57•] . The future studies should investigate whether the adjunct of an anticoagulant (either warfarin or heparin) to omalizumab or ciclosporin leads to a better control of the disease in patients not responding to these drugs.
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